These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32225075)

  • 1. Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data.
    Krahel JA; Baran A; Kamiński TW; Maciaszek M; Flisiak I
    J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32225075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis.
    Frątczak A; Miziołek B; Łupicka-Słowik A; Sieńczyk M; Polak K; Bergler-Czop B
    Life (Basel); 2023 Sep; 13(9):. PubMed ID: 37763277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
    Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
    [No Abstract]   [Full Text] [Related]  

  • 4. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
    Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
    Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.
    Baran A; Kiluk P; Maciaszek M; Świderska M; Flisiak I
    Arch Dermatol Res; 2019 Jul; 311(5):389-397. PubMed ID: 30993401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.
    Fang C; Luo T; Lin L
    Ann Transl Med; 2018 Dec; 6(23):452. PubMed ID: 30603640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus.
    Frątczak A; Polak K; Szczepanek M; Lis-Święty A
    Postepy Dermatol Alergol; 2022 Aug; 39(4):645-650. PubMed ID: 36090718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
    Pu S; Rodríguez-Pérez C; Ramprasath VR; Segura-Carretero A; Jones PJ
    Vascul Pharmacol; 2016 Dec; 87():60-65. PubMed ID: 27374222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response.
    Heinzl MW; Resl M; Klammer C; Egger M; Dieplinger B; Clodi M
    Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31843964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes.
    Fazaeli M; Khoshdel A; Shafiepour M; Rohban M
    Diabetes Metab Syndr; 2019; 13(1):312-316. PubMed ID: 30641718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.